Corbus Pharmaceuticals Analyst Ratings
Corbus Pharmaceuticals Analyst Ratings
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $0.00 to $22.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $6.44, which is within the analyst's predicted range.| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 08/09/2023 | 241.61% | Oppenheimer | → $22 | Reiterates | Outperform → Outperform |
| 05/10/2023 | 241.61% | Oppenheimer | → $22 | Upgrades | Perform → Outperform |
| 03/08/2023 | -53.42% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 02/14/2023 | -53.42% | HC Wainwright & Co. | → $3 | Reiterates | → Buy |
| 10/08/2020 | -53.42% | HC Wainwright & Co. | $6 → $3 | Maintains | Buy |
| 09/09/2020 | -6.83% | HC Wainwright & Co. | $24 → $6 | Maintains | Buy |
| 09/08/2020 | — | Roth Capital | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | BTIG | Downgrades | Buy → Neutral | |
| 09/08/2020 | — | RBC Capital | Downgrades | Outperform → Sector Perform | |
| 06/17/2020 | 241.61% | BTIG | → $22 | Initiates Coverage On | → Buy |
| 06/04/2020 | 396.89% | Nomura | $12 → $32 | Maintains | Buy |
| 03/26/2020 | 1639.13% | Nomura | → $112 | Initiates Coverage On | → Buy |
| 04/05/2019 | 179.5% | Jefferies | → $18 | Initiates Coverage On | → Buy |
| 03/19/2019 | 334.78% | Oppenheimer | → $28 | Initiates Coverage On | → Outperform |
| 12/26/2018 | 272.67% | HC Wainwright & Co. | → $24 | Initiates Coverage On | → Buy |
| 12/07/2018 | 257.14% | RBC Capital | → $23 | Initiates Coverage On | → Outperform |
| 10/24/2018 | 241.61% | B. Riley Securities | → $22 | Initiates Coverage On | → Buy |
| 09/14/2018 | 459.01% | Cantor Fitzgerald | $32 → $36 | Maintains | Overweight |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 08/09/2023 | 241.61% | 奥本海默 | → 22 美元 | 重申 | 跑赢大盘 → 跑赢大盘 |
| 05/10/2023 | 241.61% | 奥本海默 | → 22 美元 | 升级 | 表现 → 跑赢大盘 |
| 03/08/2023 | -53.42% | HC Wainwright & Co. | → 3 美元 | 重申 | → 购买 |
| 02/14/2023 | -53.42% | HC Wainwright & Co. | → 3 美元 | 重申 | → 购买 |
| 2020 年 8 月 10 日 | -53.42% | HC Wainwright & Co. | 6 美元 → 3 美元 | 维持 | 购买 |
| 2020 年 9 月 9 日 | -6.83% | HC Wainwright & Co. | 24 美元 → 6 美元 | 维持 | 购买 |
| 2020 年 8 月 9 日 | — | 罗斯资本 | 降级 | 买入 → 中性 | |
| 2020 年 8 月 9 日 | — | BTIG | 降级 | 买入 → 中性 | |
| 2020 年 8 月 9 日 | — | 加拿大皇家银行资本 | 降级 | 跑赢大盘 → 行业表现 | |
| 2020 年 6 月 17 日 | 241.61% | BTIG | → 22 美元 | 启动覆盖范围开启 | → 购买 |
| 06/04/2020 | 396.89% | 野村 | 12 美元 → 32 美元 | 维持 | 购买 |
| 2020 年 3 月 26 日 | 1639.13% | 野村 | → 112 美元 | 启动覆盖范围开启 | → 购买 |
| 2019 年 5 月 4 日 | 179.5% | 杰富瑞集团 | → 18 美元 | 启动覆盖范围开启 | → 购买 |
| 03/19/2019 | 334.78% | 奥本海默 | → 28 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 12/26/2018 | 272.67% | HC Wainwright & Co. | → 24 美元 | 启动覆盖范围开启 | → 购买 |
| 2018 年 7 月 12 日 | 257.14% | 加拿大皇家银行资本 | → 23 美元 | 启动覆盖范围开启 | → 跑赢大盘 |
| 2018 年 10 月 24 日 | 241.61% | B. 莱利证券 | → 22 美元 | 启动覆盖范围开启 | → 购买 |
| 09/14/2018 | 459.01% | 坎托·菲茨杰拉德 | 32 美元 → 36 美元 | 维持 | 超重 |
What is the target price for Corbus Pharmaceuticals (CRBP)?
Corbus Pharmicals（CRBP）的目标价格是多少？
The latest price target for Corbus Pharmaceuticals (NASDAQ: CRBP) was reported by Oppenheimer on August 9, 2023. The analyst firm set a price target for $22.00 expecting CRBP to rise to within 12 months (a possible 241.61% upside). 4 analyst firms have reported ratings in the last year.
奥本海默于2023年8月9日公布了Corbus Pharmicals（纳斯达克股票代码：CRBP）的最新目标股价。这家分析公司将目标股价定为22.00美元，预计CRBP将在12个月内升至241.61％（可能上涨241.61％）。去年有4家分析公司公布了评级。
What is the most recent analyst rating for Corbus Pharmaceuticals (CRBP)?
Corbus Pharmicals（CRBP）的最新分析师评级是多少？
The latest analyst rating for Corbus Pharmaceuticals (NASDAQ: CRBP) was provided by Oppenheimer, and Corbus Pharmaceuticals reiterated their outperform rating.
Corbus Pharmicals（纳斯达克股票代码：CRBP）的最新分析师评级由奥本海默提供，Corbus Pharmicals重申了其表现跑赢大盘的评级。
When is the next analyst rating going to be posted or updated for Corbus Pharmaceuticals (CRBP)?
Corbus Pharmicals（CRBP）的下一个分析师评级何时公布或更新？
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Corbus Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Corbus Pharmaceuticals was filed on August 9, 2023 so you should expect the next rating to be made available sometime around August 9, 2024.
分析师在进行了广泛的研究（包括浏览公开财务报表、与Corbus Pharmicals的高管和客户交谈以及听取财报电话会议）后得出了股票评级。大多数分析师每三个月进行一次评级，因此每家公司每年应该获得4个评级。Corbus Pharmicals的最新评级是在2023年8月9日提交的，因此您应该预计下一个评级将在2024年8月9日左右公布。
Is the Analyst Rating Corbus Pharmaceuticals (CRBP) correct?
分析师对Corbus Pharmicals（CRBP）的评级正确吗？
While ratings are subjective and will change, the latest Corbus Pharmaceuticals (CRBP) rating was a reiterated with a price target of $0.00 to $22.00. The current price Corbus Pharmaceuticals (CRBP) is trading at is $6.44, which is within the analyst's predicted range.
尽管评级是主观的，将会发生变化，但最新的Corbus Pharmicals（CRBP）评级得到了重申，目标股价为0.00美元至22.00美元。Corbus Pharmicals（CRBP）目前的交易价格为6.44美元，在分析师的预测区间内。